A recent investigation from Spotlight PA highlights that some Pennsylvania cannabis companies use misleading or incomplete claims in order to promote marijuana as a treatment for opioid addiction, causing patients’ lives to be at a greater risk.

In the investigation, Spotlight PA identified over 60 websites that offered services in-state, ranging from cannabis dispensaries to medical marijuana certification groups, that made misleading claims and cited scientific evidence out of context. One popular claim includes research suggesting marijuana is a ‘viable substitute’ for an FDA-approved drug to treat opioid use disorder. Seven websites promoted the benefits of CBD for reducing opioid cravings and withdrawal symptoms.

These claims are backed by dubious evidence, including outdated scientific studies, cherry-picked data, and medical research by officials associated with the companies. Several health experts, along with cannabis researchers and medical providers, claim that this information is inaccurate, misleading, and possibly dangerous. By saying medical marijuana is a safe alternative to FDA-approved opioid use disorder treatment, these companies are not putting the safety of their patients first.

If you have encountered these claim or similar ones regarding medical marijuana and opioid use disorder treatment, let Shub Law know. Email us at leads@shublawyers.com or call at (856) 772-7200 to speak to an expert attorney today.